Join to View Full Profile
300 George StNew Haven, CT 06510
Phone+1 410-299-1044
Dr. Lustberg is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Ohio State University HospitalFellowship, Hematology and Medical Oncology, 2007 - 2009
University of MarylandResidency, Internal Medicine, 2003 - 2006
University of Maryland School of MedicineClass of 2003
Certifications & Licensure
CT State Medical License 2021 - 2025
OH State Medical License 2007 - 2022
MD State Medical License 2006 - 2008
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 2 citationsPatient preferences for CDK4/6 inhibitor treatments in HR+/HER2- early breast cancer: a discrete choice survey study.Erica L Mayer, Mary Lou Smith, Annie Guérin, Dominick Latremouille-Viau, Nisha C Hazra
Breast Cancer Research and Treatment. 2025-05-01 - The unmet needs of breast cancer survivors: is menopausal hormone therapy ever an option?Amy Comander, Maryam B Lustberg, Lisa Larkin
Menopause. 2025-05-01 - Combined Treatment With Cognitive Behavioral Therapy for Insomnia and Acceptance and Commitment Therapy Enhances Objective and Subjective Reports of Sleep in Patients ...Sharla Wells-Di Gregorio, Stacy Flowers, Juan Peng, Donald R Marks, Danielle Probst
Psycho-Oncology. 2025-04-01
Press Mentions
Improving Breast Cancer Outcomes with Dr. Maryam LustbergMarch 31st, 2025- Sticking with CDK4/6 Inhibitors for Breast Cancer Wins in Post-Progression SettingDecember 20th, 2024
- New Video: Navigating Breast Cancer Treatment OptionsOctober 11th, 2024
- Join now to see all
Grant Support
- Dance-based Avenues to Advance Nonpharmacologic treatment of Chemotherapy Effects (DAANCE): a multicenter trialOHIO STATE UNIVERSITY2024–2029
- Prevention of paclitaxel-induced peripheral neuropathy with nilotinibOHIO STATE UNIVERSITY2019–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
